Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Pulmonary Fibrosis

Financiado

Cerrado

Glycomic and Genomic Repercussion of Nebulisable Gal 3 Inhibitory Medical Device...

Glycomic and Genomic Repercussion of Nebulisable Gal 3 Inhibitory Medical Device Treatment in Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis (IPF) accounts for a progressive pathology with extremely high mortality and no cure available. There is a need to study pathology mechanisms for efficient treatments development. Galectin-3 (Gal-3) h... ver más

31/08/2025

OLLSCOIL NA GAILLI...

258K€

Presupuesto del proyecto: 258K€

Líder del proyecto

UNIVERSITY OF GALWAY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-04-12

MSCA-IF-2020: Individual Fellowships

I+D

Cerrada hace 4 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

OLLSCOIL NA GAILLIMHE

257.56K€ | Lider

YALE UNIVERSITY

165.27K€ | Participante

Proyectos interesantes

STAR-TEL

Medical Technol...

Data Science

1M€ Cerrado

LUNG-BIOREPAIR

Medical Technol...

Biotechnology

3M€ Cerrado

DEPRONIL

Medical Technol...

Data Science

229K€ Cerrado

MORPHOMICS-IPF

Medical Technol...

Data Science

190K€ Cerrado

FIBREX

Medical Technol...

Data Science

2M€ Cerrado

TOPFIBRO

Medical Technol...

Pharmaceutical...

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 52 meses Fecha Inicio: 2021-04-12
Fecha Fin: 2025-08-31

Líder del proyecto

UNIVERSITY OF GALWAY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 258K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Idiopathic Pulmonary Fibrosis (IPF) accounts for a progressive pathology with extremely high mortality and no cure available. There is a need to study pathology mechanisms for efficient treatments development. Galectin-3 (Gal-3) has shown promising effects in slowing down IPF. In this project, I will optimise nebulisation of a novel Gal-3 inhibitory drug (TD139) hydrogel treatment in bleomycin-induced PF mice model, perform an exhaustive genomic analysis to assess single-cell RNA trajectories during pathology recovery, and analyse tissue glycosylation patters for disease correlation. All this will allow for information on diseases and healing mechanisms to development efficient biomaterials treatments and contribute to the 3rd Sustainable Development Goal of the United Nations Good Health and Well-Being for all. I will perform nebulisation studies during secondment in specialised aerosol drug delivery industry (Aerogen®/John Power) (Ireland), in vivo model and exhaustive genomic analysis during outgoing phase in IPF genomic expert lab (Prof Kaminski) at PCCSM, Yale School of Medicine (US), and thorough lectin microarray analysis during incoming phase in glycolbiologist and biomaterials expert lab (Prof Pandit) at CÚRAM, NUI Galway (Ireland). The high expertise of the supervisors, my expertise in biomaterials, the highly qualified and prestigious hosts infrastructures and the intersectoral, international and interdisciplinary aspects of the action will promote my skills for eligibility for the EU Research Council Starting Grant. This will allow me to stablish a Biomaterial Therapies Critical Mass for Respiratory Diseases (RD) in EU and comply with the EU Respiratory Society objective to promote scientific excellence to alleviate suffering of RD. In addition, I will work in a detailed career development plan to promote translation, research integrity, inclusion of minorities, audience engagement and gender dimension for a more impactful and representative research.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores